Skip to main content
Start date: 
ECRAID-Prime Primary Care

ECRAID-Prime

27 sites
8 countries
35 patients enrolled

ECRAID-Prime is pioneering Europe's first adaptive platform trial aimed at evaluating new treatments for COVID-19 and COVID-like illnesses within community and primary care settings. This double-blind, randomised, comparative study focuses on the effects of Investigational Medicinal Products (IMPs) in non-hospitalised patients.

 

Compared to traditional trials, the adaptive platform trial protocol allows multiple investigational products or treatments for the same condition to be tested simultaneously, with the flexibility to add new interventions as they are developed. This innovative approach enhances the trial's efficiency and flexibility, accelerating the identification of effective treatments, and enables healthcare providers to refine their strategies in response to future outbreaks or pandemics. 

“COVID-19 and COVID-like illness continue to have a profound impact on public health particularly within primary care and community settings, where the burden is the greatest. It is in these settings that early treatment options can deliver the most significant benefits. Our trial is focussed on finding effective treatments and making them available to those who need them most.” – Chris Butler, Principal Investigator

The EU-funded trial launched in October 2024, with Nitric Oxide Nasal Spray (NONS) and Saline nasal spray as the first investigational drugs being tested. We are committed to advancing our research with additional therapeutics for a longer period of time, and will provide updates as the study progresses. 

 

More information

Read more about our studies. Have a question? Get in touch with Coordinating Investigator Alike van der Velden at A.W.vanderVelden@umcutrecht.nl